ArticleNature communications2026
Deviations from genetic additivity driven by rare variants at biobank scale.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deviations from genetic additivity driven by rare variants at biobank scale.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Additive genetic models are the default for genome-wide association studies, but deviations from additivity are crucial for understanding disease mechanisms and therapeutic responses. Yet existing methods for testing nonadditivity are computationally infeasible for large-scale analysis or rely on Hardy-Weinberg assumptions, making them unsuitable for rare variants in large biobanks. We use an orthogonal allelic recoding framework that enables scalable testing of nonadditive genetic effects without Hardy-Weinberg assumptions while integrating seamlessly with existing linear mixed models. Analyzing up to 399,943 UK Biobank individuals across 2906 plasma proteins and 55 quantitative traits, we demonstrate that approximately one-third of cognate gene-protein relationships exhibit nonlinear dose responses. We identify recessive effects, including FUT10 variants associated with reduced lung function, and validate these findings in the All of Us cohort. We show that many complex traits show partial recessivity, reconciling conflicting inheritance patterns in the literature, and that joint two-degree-of-freedom models substantially improve statistical power when the underlying trait is partially recessive. Our framework efficiently partitions additive and nonadditive heritability components at biobank scale, providing a quantitative map of gene dose-response relationships with direct implications for therapeutic target identification and precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.